Table 1 Pre-biologic health care experience among patients with ulcerative colitis, n = 1891
Time window prior to biologic exposure index datea (calendar date range, pre-index days covered) | ||||||
|---|---|---|---|---|---|---|
Year-5 (− 1825 to − 1461) | Year-4 (− 1460 to − 1081) | Year-3 (− 1080 to − 721) | Year-2 (− 720 to − 366) | Year-1 (− 365 to − 1) | All 5 years (− 1825 to − 1) | |
Oral corticosteroids exposure | ||||||
≥ 1 prescription, n (% of 1891) | 603 (32) | 663 (35) | 752 (40) | 874 (46) | 1571 (83) | 1781 (94) |
Duration of exposure, days | ||||||
Mean (SD) | 70.8 (87.9) | 69.0 (86.1) | 70.4 (89.7) | 79.5 (86.6) | 108.4 (88.9) | 214.0 (257.9) |
Median (IQR) | 34 (12–90) | 34 (12–90) | 36 (12–90) | 52 (21–106) | 88 (49–146) | 145 (71–254) |
Prednisone equivalent milligrams | ||||||
Mean (SD) | 743.8 (987.4) | 824.5 (1343.2) | 932.7 (1608.1) | 1132.9 (1733.8) | 1659.2 (1906.7) | 2972.0 (4160.5) |
Median (IQR) | 360 (120–920) | 360 (114–950) | 384 (120–1050) | 570 (190–1298) | 1080 (510–2130) | 1758 (824–3540) |
5-Aminosalisylates (5-ASA) | ||||||
≥ 1 prescription, n (% of 1891) | 1119 (59) | 1176 (62) | 1211 (64) | 1304 (69) | 1608 (85) | 1768 (93) |
# of different products/formulations | ||||||
Mean (SD) | 1.5 (0.7) | 1.5 (0.7) | 1.5 (0.8) | 1.5 (0.7) | 1.8 (0.9) | 2.8 (1.4) |
Median (IQR) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 1 (1–2) | 2 (1–2) | 3 (2–4) |
≥ 1 prescription of oral 5-ASA, n (% of 1891) | 1077 (57) | 1135 (60) | 1162 (61) | 1244 (66) | 1557 (82) | 1731 (92) |
Duration of oral 5-ASA, days | ||||||
Mean (SD) | 246.1 (117.2) | 237.4 (118.6) | 245.1 (121.3) | 243.2 (119.7) | 232.1 (123.7) | 856.8 (613.6) |
Median (IQR) | 270 (150–345) | 270 (150–330) | 270 (150–360) | 270 (150–360) | 240 (120–330) | 796 (270–1380) |
Other immunomodulators (IMM)b | ||||||
≥ 1 oral prescription, n (% of 1891) | 343 (18) | 357 (19) | 376 (20) | 440 (23) | 700 (37) | 879 (46) |
Duration of other oral IMM, days | ||||||
Mean (SD) | 234.5 (125.9) | 239.3 (123.1) | 238.7 (125.4) | 231.1 (125.8) | 198.2 (132.3) | 564.4 (570.3) |
Median (IQR) | 270 (120–360) | 270 (150–360) | 270 (120–360) | 252 (112–360) | 180 (70–324) | 300 (90–960) |
All-Cause Health care utilization | ||||||
≥ 1 outpatient visit, n (% of 1891) | 1833 (97) | 1834 (97) | 1849 (98) | 1845 (98) | 1889 (100) | 1891 (100) |
Outpatient visits, # of times | ||||||
Mean (SD) | 14.4 (14.3) | 14.8 (13.8) | 15.8 (16.2) | 17.0 (15.8) | 22.8 (15.4) | 83.0 (59.8) |
Median (IQR) | 10 (5–18) | 11 (6–19) | 12 (6–20) | 12 (7–22) | 19 (2–29) | 4 (1–103) |
≥ 1 Emergency department visits, n (% of 1891) | 354 (19) | 401 (21) | 381 (20) | 416 (22) | 692 (37) | 1241 (66) |
Emergency department visit, # of times | ||||||
Total | 554 | 668 | 594 | 667 | 1295 | 3778 |
Mean | 1.6 | 1.7 | 1.6 | 1.6 | 1.9 | 3.0 |
≥ 1 inpatient stay, n (% of 1891) | 153 (8) | 152 (8) | 168 (9) | 183 (10) | 475 (25) | 824 (44) |
In-patient stays, # of times | ||||||
Total | 208 | 201 | 239 | 238 | 672 | 1558 |
Mean | 1.4 | 1.3 | 1.4 | 1.3 | 1.4 | 1.9 |
≥ 1 inpatient stay with an infection, n (% of 1891) | 20 (1) | 33 (2) | 29 (2) | 48 (3) | 125 (7) | 230 (12) |
Hospitalized infections, # of times | ||||||
Total | 31 | 60 | 74 | 115 | 234 | 514 |
Mean | 1.6 | 1.8 | 2.6 | 2.4 | 1.9 | 2.2 |